Subsidy Information and Financing Scheme MAFFaricimab (Vabysmo) Injection 6 mg/0.05 mL 1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degenera... See all × MAFFaricimab (Vabysmo) Injection 6 mg/0.05 mL 1) Treatment of adults with visual impairment due to neovascular (wet) age-related macular degeneration. 2) Treatment of adults with visual impairment due to diabetic macular oedema.
Drug Guidance for Subsidy 16/09/2025 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration The Ministry of Health’s Drug Advisory Committee has recommended: Aflibercept 2 mg/0.05 mL pr... See all × 16/09/2025 Anti-vascular endothelial growth factors for treating diabetic macular oedema and age-related macular degeneration The Ministry of Health’s Drug Advisory Committee has recommended: Aflibercept 2 mg/0.05 mL prefilled syringe and vial; and Faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to: diabetic macular oedema; and neovascular (wet) age-related macular degeneration. Funding status RAflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 November 2025. RFaricimab 6 mg/0.05 mL vial is recommended for inclusion on the MAF for the abovementioned indications from 1 March 2024. NRMAF assistance does not apply to other formulation(s) or strengths(s) of aflibercept and faricimab for treating diabetic macular oedema or neovascular age-related macular degeneration. 16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL pref... See all × 16/09/2025 Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL prefilled syringe and vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion. The Ministry of Health’s Drug Advisory Committee has not recommended faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion, due to the unacceptable pricing proposal from the company. Funding status RAflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025. NRMAF assistance does not apply to faricimab, and other formulation(s) or strengths(s) of aflibercept for the abovementioned indication.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Vabysmo Injection 6 mg/0.05 mL Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Singapore National Eye Centre Tan Tock Seng Hospital Woodlands Health Campus